Cognitive impairment, including impaired social cognition, is largely responsible for the deterioration in social life suffered by patients with psychiatric disorders, such as schizophrenia and major depressive disorder (MDD). Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quino-lin-2(1H)-one), a novel serotonin-dopamine activity modulator, was developed to offer efficacious and tolerable therapy for different psychiatric disorders, including schizophrenia and adjunctive treatment of MDD. In this study, we investigated whether brexpiprazole could improve social recognition deficits (one of social cognition deficits) in mice, after administration of the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 (dizocilpine). Dosing with dizocilpine (0.1 mg/kg) induced significant impairment of social recognition in mice. Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) significantly ameliorated dizocilpine-induced social recognition deficits, without sedation or a reduction of exploratory behavior. In addition, brexpiprazole alone had no effect on social recognition in untreated control mice. By contrast, neither risperidone (0.03 mg/kg, p.o.) nor olanzapine (0.03 mg/kg, p.o.) altered dizocilpine-induced social recognition deficits. Finally, the effect of brexpiprazole on dizocilpine-induced social recognition deficits was antagonized by WAY-100,635, a selective serotonin 5-HT 1A antagonist. These results suggest that brexpiprazole could improve dizocilpine-induced social recognition deficits via 5-HT 1A receptor activation in mice. Therefore, brexpiprazole may confer a beneficial effect on social cognition deficits in patients with psychiatric disorders.
Introduction
Cognitive impairment describes a diverse range of deficits, seen in psychiatric disorders. Of these, impaired social cognition greatly hampers everyday life, resulting in poor work productivity or underemployment of patients with schizophrenia and major depressive disorder (MDD) (Tandberg et al., 2011; Tse et al., 2013; Horan et al., 2012; Lo and Siu, in press) . It is generally accepted that reducing social cognitive dysfunction is an important factor in assisting psychiatric patients to make healthy adjustments in their social lives (Tandberg et al., 2011; Tse et al., 2013; Horan et al., 2012; Trapp et al., 2013) . Current reports suggest that training of social cognition may help to improve functional outcome in patients with schizophrenia (Henderson, 2013) . To complement this, the development of novel drugs to improve social cognition deficits in patients with schizophrenia is also imperative.
Social recognition testing is designed to measure the propensity of a mouse to make contact with a novel rather than familiar mouse. This testing therefore represents a cognitive model that reflects innate ability to communicate with others van der Kooij and Sandi, 2012) . Social recognition test in rodents is also one of the assays for evaluating social cognition in humans (Millan and Bales, 2013) . Based on the N-methyl-D-aspartate (NMDA) hypofunction hypothesis of schizophrenia (Hashimoto, 2006 (Hashimoto, , 2014 Hashimoto et al., 2013) , the NMDA receptor antagonist, (+)-MK-801 (dizocilpine), is widely used to induce schizophrenia-like behavioral abnormalities, including positive and negative symptoms and cognitive deficits in rodents (Hashimoto et al., 2009; Karasawa et al., 2008; Rajagopal et al., 2014; Meltzer et al., 2011; Okamura et al., 2004; Rogoz, 2013; Zhang et al., 2007) . Furthermore, dizocilpine also impairs social interaction and social recognition (Maehara et al., 2011; Oh et al., 2013; Hikichi et al., 2013) .
Brexpiprazole, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy} quinolin-2(1H)-one, is a novel serotonin-dopamine activity modulator with high affinity for serotonin, dopamine and noradrenaline receptors (Maeda et al., 2014a) . It is a partial agonist at serotonin 5-HT 1A and dopamine D 2 receptors, with a relatively equal potency, and an antagonist at 5-HT 2A receptors and adrenergic α 1B/2C receptors. Brexpiprazole is currently under clinical evaluation and expected to show efficacy and tolerability when used as therapy for different psychiatric disorders, including schizophrenia and adjunctive treatment for MDD. Very recently, brexpiprazole was shown to improve the NMDA receptor antagonist phencyclidine-induced cognitive deficits in the novel object recognition test in rodents (Maeda et al., 2014b; Yoshimi et al., 2014) . To date, the effect of brexpiprazole on social recognition has not been investigated. In this study, we evaluated the effects of brexpiprazole on dizocilpineinduced social recognition deficits in mice.
Experimental procedures

Animals
Male C57BL/6NCrSlc mice (Japan SLC Inc., Shizuoka, Japan) aged between 4 and 5 weeks old were selected as stranger mice, while animals between 8 and 10 weeks old were used for this study. All mice were housed in groups of five per cage, in a room maintained at 2372 1C and 60710% humidity, with a 12/12 h light/dark cycle (lights on at 7:00 a.m.). The mice were given free access to food and water. Animal care and use were conducted in accordance with the Institutional Guidelines for Animal Care and Use (Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan).
Drugs
(+)-MK-801 hydrogen maleate (dizocilpine) was purchased from Sigma-Aldrich Co., Ltd. (Tokyo, Japan). Brexpiprazole, risperidone, olanzapine and WAY-100,635 were synthesized at Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Dizocilpine was dissolved in saline and administered intraperitoneally (i.p.) at 10 ml/kg, twice daily, on the day before and 30 min prior to sociability testing. Brexpiprazole, risperidone, olanzapine and WAY-100,635 were dissolved in 5% (w/v) gum Arabic and administered orally (p.o.), at 10 ml/kg, 1 h prior to sociability testing. The doses of dizocilpine (0.1 mg/kg) and WAY-100,635 (1.0 mg/kg) were selected from previously published reports in mice (Hagiwara et al., 2008; Hashimoto et al., 2009; Takatsu et al., 2011; Yoshimi et al., 2014; Zhang et al., 2007) . The doses of antipsychotic drugs were selected based on doses that did not impact locomotion (data not shown).
Apparatus
The test apparatus consisted of a rectangular, three-chambered box, and a lid with an attached infrared video camera (O'Hara & Co., Ltd., Tokyo, Japan). The apparatus was 610W Â 400D Â 220H mm 3 , and the dividing walls were made from clear Plexiglass, with small square openings (3 Â 5 cm 2 ) allowing access into each chamber. The stranger mouse was enclosed in a small, round wire cage (diameter, 10 cm; height, 12 cm), allowing olfactory, visual, auditory, and tactile contact, but no deep contact. Using a CCD camera, measures were taken of the amount of time spent around the wire cage. The total distance traveled was calculated based on traced mice movement and presented as the locomotor activity in this study. All data were computerized. Activity was monitored and analyzed using applications based on the public domain NIH Image or Image J program (developed by Wayne Rasband at the U.S. National Institute of Mental Health and available on the Internet at http://rsb.info.nih. gov/nih-image/) (O'Hara & Co., Ltd., Tokyo, Japan).
Behavioral procedures
The measurement of sociability and social recognition was performed using the same procedure described in previous reports (Moy et al., 2007; Nakatani et al., 2009; Matsuo et al., 2009; Riedel et al., 2009) . In this study, we focused on a narrowly defined set of parameters.
Habituation
Mice were randomly assigned to groups. Mice were first placed in the middle compartment of the apparatus and allowed to explore freely for 6 min. All other compartments were empty during this habituation period.
Sociability test
An unfamiliar male (stranger) that had no prior contact with the mouse was placed in one of the side chambers. After the habituation period, the unfamiliar male juvenile mouse (stranger 1) was placed inside the round wire cage, in one of the side compartments (randomly selected and counterbalanced for each group). The opposite compartment was empty. The mice were able to freely explore all three compartments of the apparatus for 6 min. The time spent around cages (stranger 1 or empty) was calculated as direct contact.
Social recognition test
After sociability testing, a novel unfamiliar juvenile mouse (stranger 2) was placed inside a new round wire cage and introduced to the 'empty compartment' of the apparatus. Mice were confined to the central compartment and were able to explore freely in all compartments for 10 min.
The recognition index (RI) was calculated using parameters measured during social recognition sessions and was defined as the quotient of the time the mouse spent around the novel juvenile (stranger 2) divided by the sum of the time spent around the familiar (stranger 1) and novel (stranger 2) juvenile mice.
Statistical analyses
All statistical analyses were performed using Prism 5 (GraphPad Software Inc., La Jolla, USA). Data are presented as mean7standard error of the mean (S.E.M.). To determine the effects of drug treatment, one-way ANOVA, followed by the post-hoc Bonferroni test (for RI and total distance) or a two-tailed paired t-test (for RI and time spent around cage), was used. p Values of less than 0.05 were considered statistically significant.
Results
Effects of brexpiprazole on dizocilpineinduced social recognition deficits
Mice in all groups spent significantly more time around stranger 1, than the empty area in sociability sessions (data not shown). A one-way ANOVA on RI in social recognition session showed a significant effect of treatment (F (4, 56) =5.83, po0.001) ( Figure 1A ). Saline-treated control mice had a significant preference for spending more time with the novel unfamiliar stranger 2, in comparison with familiar stranger 1, in the social recognition session ( Figure 1B ). Treatment with dizocilpine (0.1 mg/kg, i.p.) significantly decreased the total time spent around stranger 2 in social recognition sessions. A paired t-test showed a significant (po0.01) impairment of RI in the dizocilpine-treated group. Mice spent the same amount of time interacting with stranger 1 and stranger 2 mice ( Figure 1A and B). The total distance moved (exploratory behavior), indicative of locomotor activity, was significantly increased by dizocilpine administration ( Figure 1C ). Figure 1 Effects of brexpiprazole on dizocilpine-induced social recognition deficits. Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) was administered twice daily on the day before and 30 min prior to sociability testing. Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. (A) Social recognition was measured by the recognition index (RI), that is, the quotient of time the subject mouse spent around the novel juvenile (stranger 2) mouse divided by the sum of the time spent around the familiar (stranger 1) and novel juvenile (stranger 2) mice during social recognition sessions. (B) Duration of time spent around each stranger during the social recognition sessions and, (C) exploratory behavior during social recognition sessions. Values are the mean7S. E.M (n=11-15). *po0.05, **po0.01, ***po0.001 compared with dizocilpine+vehicle group (A and C, one-way ANOVA, followed by post-hoc Bonferroni test). **po0.01, ***po0.001 compared with stranger 1 mice (B, two-tailed paired t-test). Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of brexpiprazole on the RI (D), duration of time spent around each stranger mouse (E), and exploratory behavior (F), during social recognition sessions. Values are the mean7S.E.M (n=7-14). *po0.05, **po0.01, ***po0.001 compared with stranger 1 (E, two-tailed paired t-test). N.S.: not significant.
Next, we examined whether brexpiprazole attenuated dizocilpine-induced social recognition deficits in mice. Neither dizocilpine (0.1 mg/kg, i.p.) nor brexpiprazole (0.01, 0.03 and 0.1 mg/kg, p.o.) altered the amount of time spent around stranger 1 mice in sociability sessions (data not shown). However, at all three doses of brexpiprazole, mice treated with brexpiprazole showed a significant preference for spending more time with novel unfamiliar stranger 2 mice, compared with familiar stranger 1 mice in social recognition sessions ( Figure 1B) , and additionally, impaired RI was significantly restored by treatment with brexpiprazole at the same doses used in sociability testing ( Figure 1A) . Furthermore, brexpiprazole (0.01, 0.03 and 0.1 mg/kg) did not temper the increased locomotor activity induced by dizocilpine in social recognition sessions ( Figure 1C ).
Brexpiprazole alone did not affect social recognition or exploratory behavior
We examined the effect of brexpiprazole on social recognition in untreated control mice. Treatment with brexpiprazole (0.01, 0.03 and 0.1 mg/kg) had no effect on the time spent around stranger 1 mice in either sociability (data not shown) or social recognition sessions ( Figure 1D and E). Brexpiprazole did not alter RI in social recognition sessions ( Figure 1D ), nor did it have an effect on exploratory behavior during either session ( Figure 1F ).
3.3. Risperidone and olanzapine had no effect on dizocilpine-induced social recognition deficits
We examined whether the atypical antipsychotic drugs, risperidone and olanzapine, affected dizocilpine-induced social recognition deficits in mice. A one-way ANOVA on RI in social recognition session showed a significant effect of treatment (F (2, 31) =4.60, po0.05) (Figure 2A) . Post-hoc analysis showed that risperidone (0.03 mg/kg, p.o.) did not ameliorate dizocilpineinduced social recognition deficits (Figure 2A and B) , and dizocilpine-induced hyperlocomotion in the recognition sessions ( Figure 2C ). When administered alone, risperidone (0.03 mg/kg, p.o.) significantly decreased both RI and locomotor activity in untreated control mice ( Figure 2D-F) .
A one-way ANOVA on RI in social recognition session showed a significant effect of treatment (F (2, 27) =7.72, po0.01) Figure 2 Effect of risperidone on dizocilpine-induced social recognition deficits. Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) was administered twice daily on the day before and 30 min prior to sociability testing. Risperidone (0.03 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of risperidone on RI (A), duration of time spent around each stranger mouse (B), and exploratory behavior (C) during social recognition sessions. Values are the mean7S.E.M (n =11 or 12). *po0.05 compared with dizocilpine + vehicle group (A and C, one-way ANOVA, followed by post-hoc Bonferroni test). N.S.: not significant. **po0.01 compared with stranger 1 mice (B, two-tailed paired t-test). Risperidone (0.03 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of risperidone on RI (D), duration of time spent around each stranger mouse (E) and exploratory behavior (F) during social recognition sessions. Values are the mean7S.E.M (n =7). *po0.05 compared with the vehicle-treated control group (D and F, two-tailed paired t-test). *po0.05, ***po0.001 compared with stranger 1 mice (E, two-tailed paired t-test).
( Figure 3A) . Post-hoc analysis showed that olanzapine (0.03 mg/ kg, p.o.) did not affect time spent around stranger 2 mice, nor did it reverse dizocilpine-induced impairment of the RI ( Figure 3A and B). Furthermore, olanzapine had no effect on dizocilpine-induced hyperlocomotion in the recognition sessions ( Figure 3C ). Olanzapine (0.03 mg/kg, p.o.) alone was incapable of altering RI, the time spent around stranger 2 mice, or exploratory behavior in untreated control mice ( Figure 3D-F) .
Role of the 5-HT 1A receptor in brexpiprazole's effects on dizocilpine-induced social recognition deficits
To investigate the function of serotonin 5-HT 1A receptors in the pharmacological effect of brexpiprazole on dizocilpineinduced social recognition deficits, we examined the effect of WAY-100,635, a selective 5-HT 1A receptor antagonist. A one-way ANOVA on RI in social recognition session showed a significant effect of treatment (F (4, 57) = 7.82, po0.0001) ( Figure 4A ). Post-hoc analysis showed that WAY-100,635 (1.0 mg/kg, p.o.) significantly antagonized the effect of brexpiprazole on dizocilpine-induced social recognition deficits ( Figure 4A and B). Treatment with WAY-100,635 alone did not alter RI and locomotion in dizocilpine-treated mice ( Figure 4A and C) . Furthermore, treatment with WAY-100,635 alone did not affect RI, the time spent around stranger 2 mice, or exploratory behavior in untreated control mice ( Figure 4D-F) .
Discussion
The two major findings of this study are that the novel serotonin-dopamine activity modulator brexpiprazole, but not risperidone or olanzapine, improved social recognition deficits in mice after the administration of dizocilpine, and that 5-HT 1A receptors are critical to this beneficial effect. Antipsychotic drugs, such as risperidone and olanzapine, are known to show limited efficacy in cognitive impairment, including social recognition in schizophrenia and depression (Sergi et al., 2007; Krakowski and Czobor, 2011; Suzuki et al., 2011; Remberk et al., 2012) , despite improving various cognitive functions in rodent disease models (Wang et al., 2007; Gumuslu et al., 2013; Mutlu et al., 2011 Mutlu et al., , 2012 Wolff and Leander, 2003) . It is of considerable clinical importance Figure 3 Effect of olanzapine on dizocilpine-induced social recognition deficits. Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) administered twice daily on the day before and 30 min prior to sociability testing. Olanzapine (0.03 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of olanzapine on RI (A), duration of time spent around each stranger mouse (B) and exploratory behavior (C) during social recognition sessions. Values are the mean7S.E.M (n =10). **po0.01, ***po0.001 compared with vehicle-treated control group for (A) and (C) (one-way ANOVA, followed by post-hoc Bonferroni test). ***po0.001 compared with stranger 1 mice for (B) (two-tailed paired t-test). Olanzapine (0.03 mg/kg, p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of olanzapine on RI (D), duration of time spent around each stranger mouse (E) and exploratory behavior (F) during social recognition sessions. Values are the mean7S. E.M (n =7). **po0.01, ***po0.001 compared with stranger 1 mice for (E) (two-tailed paired t-test). N.S.: not significant. to find new ways of improving social recognition deficits in patients with psychiatric diseases, such as schizophrenia and MDD, because of their huge negative impact on the social functioning of patients (Tandberg et al., 2011; Tse et al., 2013; Horan et al., 2012) . There are noted discrepancies in antipsychotic drug effects between rodents and humans, increasing the need for further detailed clinical studies on the effects of brexpiprazole on social recognition in patients with psychiatric diseases.
Social recognition testing is a paradigm capable of evaluating social recognition, based on the propensity of an individual mouse to spend more time with an unfamiliar mouse than with a familiar mouse (Riedel et al., 2009; Nakatani et al., 2009) . In other cognitive tests performed in rodents, mice discriminate objects by vision in the novel objective recognition test, by hearing in the fear conditioning test and by odor in the social transmission food preference test (Hashimoto et al., 2005 Boix-Trelis et al., 2007; Amann et al., 2010) . However, since social recognition testing incorporates various factors such as visual, auditory and olfactory function and some tactile stimuli needed for mouse sociability, this test provides a comprehensive evaluation of cognition in rodents, compared with other cognitive tests Moy et al., 2004 Moy et al., , 2007 . Therefore, the social recognition test in mice may represent a translational rodent model for human social cognition, since the model utilizes multiple aspects of mice socialization.
Here, we evaluated social recognition using an automated three-chambered apparatus system. This apparatus is capable of measuring the time and distance a subject mouse covers in approaching a novel mouse, thereby evaluating the subject's motivation to interact with the novel mouse. Furthermore, this system can also measure exploratory behavior by producing a representative trace of locomotor activity. This means that effects on locomotion, such as, sedation by a drug, can be easily detected. Since stranger mice were isolated individually in a wire cage, the subject mouse could interact with a stranger mouse without attack or aversive stimuli. This makes the social recognition test in mice a potential tool for assessing the efficacy of new drugs on social recognition.
We found that the 5-HT 1A antagonist, WAY-100,635, reversed the effects of brexpiprazole on dizocilpine-induced social Figure 4 Effect of a 5-HT 1A antagonist on brexpiprazole's action in the dizocilpine-induced social recognition deficits model. Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) was administered twice daily on the day before and 30 min prior to sociability testing. Brexpiprazole (Brex: 0.03 mg/kg, p.o.), WAY-100,635 (WAY: 1 mg/kg, p.o.), or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of brexpiprazole on RI (A), duration of time spent around each stranger mouse (B) and exploratory behavior (C) during social recognition sessions. Values are the mean7S.E.M (n = 11-13). *po0.05, ***po0.001 compared with dizocilpine + vehicle group, ### po0.001 compared with the dizocilpine plus brexpiprazole-treated group (A, one-way ANOVA, followed by post-hoc Bonferroni test). *po0.05, ***po0.001 compared with stranger 1 mice (B, two-tailed paired t-test). N.S.: not significant. WAY-100,635 (WAY: 1.0 mg/kg, p.o.), or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of WAY-100,635 on RI (D), duration of time spent around each stranger mouse (E) and exploratory behavior (F) during social recognition sessions were shown. Values are the mean7S.E.M (n= 7). ***po0.001 compared with stranger 1 mice (E, two-tailed paired t-test). N.S.: not significant. recognition deficits, indicating that 5-HT 1A receptors are critical to brexpiprazole's mechanism of action. A report suggests that 5-HT 1A receptor agonism is related to social recognition in rats (Millan et al., 2004) . In addition, it is reported that 5-HT 1A receptors are important in the action of other antipsychotic drugs (perospirone, aripiprazole, blonanserin), when tested in a phencyclidine-induced cognitive deficits model (Hagiwara et al., 2008; Nagai et al., 2009; Meltzer, 2012, 2013) . In contrast, WAY-100,635 could alleviate cognitive deficits in monkeys after administration of dizocilpine (Harder and Ridley, 2000) , suggesting pro-cognitive effect of 5-HT 1A receptor antagonist. However, in this study, WAY-100,635 alone had no effect in social recognition in both dizocilpine-treated and vehicle-treated control mice. Further studies of the effects of 5-HT 1A receptor agonists and antagonists on social recognition are needed. Previously, Sumiyoshi et al. (2001a Sumiyoshi et al. ( , 2001b Sumiyoshi et al. ( , 2007 reported that treatment with tandospirone (or buspirone), 5-HT 1A receptor agonists, improved cognition including executive function and verbal learning in patients with schizophrenia, indicating a key role of 5-HT 1A receptor in cognition in patients (Meltzer and Sumiyoshi, 2008; Sumiyoshi et al., 2013) . Taken together, it seems that brexpiprazole can ameliorate cognitive deficits associated with NMDA receptor dysfunction, via its 5-HT 1A agonistic activity. Further studies are needed to clarify the effects of other antipsychotic drugs with 5-HT 1A agonistic activity, on social cognition in patients.
Previous reports demonstrated that 5-HT 1A receptor antagonists impair sociability in rodents, and that 5-HT 1A receptor agonists improved sociability in the social interaction in rodents (File and Seth, 2003; Bruins Slot et al., 2005; Snigdha and Neill, 2008; Gould et al., 2011) . These findings suggest an important role of 5-HT 1A receptors in social behaviors. A recent study showed that the rewarding properties of social interaction in mice require the coordinated activity of oxytocin and 5-HT 1B receptor in the nucleus accumbens, which are implicated in the social cognitive dysfunction in patients with a number of psychiatric diseases (Dolen et al., 2013) . Since brexpiprazole has a moderate affinity at 5-HT 1B receptor (Ki=32 nM) (Maeda et al., 2014a) , it is possible that 5-HT 1B receptor may, in part, be involved in the mechanisms of action of brexpiprazole on social recognition deficits. Nonetheless, further studies of the role of 5-HT 1B receptors in the mechanisms of action of brexpiprazole would be needed to confirm this hypothesis.
In conclusion, brexpiprazole ameliorated social recognition deficits in mice after administration of dizocilpine, and the 5-HT 1A receptor antagonist WAY-100,635 reversed the effects of brexpiprazole in this model. Our results imply that brexpiprazole could potentially serve as a therapeutic drug to treat social cognitive deficits in patients with schizophrenia and MDD.
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